Anti-RBD antibody and neutralizing antibody at baseline and at one year
The baseline anti-RBD antibody (U/mL) and neutralizing antibody (%) titer in cirrhotic and HCW was 0.675 (0.4-10478) & 54.7 (0.04-1403.0) and 11.2 (-17.39-97.35) and 15.02 (-10.04-97.3) respectively. Three patients in cirrhotic group had higher levels of anti-RBD antibody and NAbs levels even before vaccination which could be due to asymptomatic natural SARSCoV-2 infection. All participants in cirrhotic and HCW group showed development of antibodies and the median titers after one year were 2132 (11.09-42594) & 8444 (101.6-23044) and 35.57 (-22.29-97.4) and 94.3 (-0.8-97.6) respectively. There was no difference between anti-RBD and neutralizing antibody titer at one year between cirrhotic and HCW group (P=0.312, P=0.277). The unvaccinated group had <0.4U/mL and <20% anti-RBD antibody (U/mL) and neutralizing antibody levels. (Figure-2)